Journal
CANADIAN JOURNAL OF CARDIOLOGY
Volume 22, Issue 11, Pages 913-927Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0828-282X(06)70310-5
Keywords
cardiovascular disease; clinical practice guidelines; dyslipidemia
Categories
Ask authors/readers for more resources
Since the last publication of the recommendations for the management and treatment of dyslipidemia, new clinical trial data have emerged that support a more vigorous approach to lipid lowering in specific patient groups. The decision was made to update the lipid guidelines in collaboration with the Canadian Cardiovascular Society. A systematic electronic search of medical literature for original research consisting of blinded, randomized controlled trials was performed. Meta-analyses of studies of the efficacy and safety of lipid-lowering therapies, and of the predictive value of established and emerging risk factors were also reviewed. All recommendations are evidence-based, and have been reviewed in detail by primary and secondary review panels. Major changes include a lower low-density lipoprotein cholesterol (LDL-C) treatment target (lower than 2.0 mmol/L) for high-risk patients, a slightly higher intervention point for the initiation of drug therapy in most low-risk individuals (LDL-C of 5.0 mmol/L or a total cholesterol to LDL-C ratio of 6.0) and recommendations regarding additional investigations of potential use in the further evaluation of coronary artery disease risk in Subjects in the moderate-risk category.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available